The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Just to delve a little bit more on the SG&A spend. I understand your outlook. But if I look at the spend in this quarter versus the last quarter, given
we have the Wockhardt integration and normalization in our branded businesses to some extent, could you explain the reason for such a moderate
increase on an absolute level? I understand the operating level -- operating leverage. But what helped offset the increase that we saw because of
the other 2 factors?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Understood. And so this digital marketing, which helps control cost, that should be sustainable, right? Or do you see this more as the markets are
opening up, probably we go back to physical marketing?
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
: Understood. My second question is on the ROW market. If I exclude Russia CIS, there seems to be a moderation quarter-on-quarter. Was there any
specific reason for that?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 28, 2020 / 12:00PM, REDY.NS - Q2 2021 Dr.Reddy's Laboratories Ltd Earnings Call
Question: Neha Manpuria - JPMorgan Chase & Co, Research Division - Analyst
:
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Just to continue on the Sputnik V, what would be the spend on trials that we plan to conduct for the vaccine in India?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Okay. And one question on the United States. So if we exclude these 9 large products that we launched in, say, the second quarter, what -- how
would -- how the base business behaved? Some perspectives on this could be helpful.
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
:
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Okay. And just last question on PSAI, on the API business. What would be the contribution for the COVID-related products in the API business?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
OCTOBER 28, 2020 / 12:00PM, REDY.NS - Q2 2021 Dr.Reddy's Laboratories Ltd Earnings Call
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: And how has been the pricing for APIs, some perspectives?
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
: Yes, sir. I mean, when we had the pandemic, there was a tight market. So does that continue? Is there a policy in currently as well? Some views over
there.
Question: Vishal Biraia - Aviva Life Insurance Company India Ltd. - Analyst
:
|